Holen Sie sich die Stockscreener-App
1.048
4.09%
-0.052
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Cardiff Oncology (CRDF) Slips to $1.02 as Biotech Stock Holds Above Key SupportNarrow Range Breakout - dars.gov.et
Cardiff Oncology Announces Upcoming Conference Participation for Mani Mohindru, Ph.D. - Quiver Quantitative
Cardiff Oncology will take part in two September cancer conferences - Stock Titan
Cardiff Oncology Inc. (CRDF) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiff Oncology Inc. (CRDF) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cardiff Oncology (NASDAQ: CRDF) seeks share boost that may dilute holders - Stock Titan
Equities Analysts Offer Predictions for CRDF Q3 Earnings - MarketBeat
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsFibonacci Extension - vinanet.vn
CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
William Blair downgrades Cardiff Oncology (CRDF) to a Hold - The Globe and Mail
CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Is Cardiff Oncology Inc (CRDF) Moving in the Right Direction Aft - GuruFocus
Cardiff Oncology: Q2 Earnings Snapshot - AOL.com
Cardiff Oncology Q2 operating expenses fall on lower R&D costs - TradingView
Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRDF Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D BurnRevenue Guidance Update - vinanet.vn
Cardiff Oncology (CRDF) Holds at $0.85 After Modest Gain; Key Resistance at $0.89 in FocusScalping Stock Signals - vinanet.vn
BlackRock, Inc. Slashes Cardiff Oncology (CRDF) Stake by 78.3% - GuruFocus
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A - Stock Titan
CRDF|Cardiff Oncology Inc|Price:0.952|Chg%:+0.023 - TradingKey
Cardiff Oncology Inc (CRDF) Balance Sheet - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011 - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Revenue Breakdown – NASDAQ:CRDF - TradingView
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Cardiff Oncology Inc (CRDF) Cash Flow - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.831|Chg%:+0.004 - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.845| - TradingKey
TradingKey - TradingKey
CRDF Q2'26 Earnings: revenue estimate is 62.78K USD - TradingView
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
CRDF Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Pipeline DevelopmentEarnings Yield Spread - vinanet.vn
Cardiff Oncology completes $10 million financing transaction - TipRanks
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock - Investing.com UK
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock By Investing.com - Investing.com Nigeria
Form 4 Cardiff Oncology Inc For: 16 July By Investing.com - Investing.com Nigeria
Cardiff Oncology Director Purchased Shares Worth Over $999K - TradingView
Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing - marketscreener.com
Cardiff Oncology (CRDF) director buys 687,285 shares and warrants - Stock Titan
Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake - Stock Titan
Cardiff Oncology Raises $10M for Onvansertib Regulatory Push - AllSci
Cardiff Oncology Announces $10 Million Registered Direct Offering to Advance Cancer Therapy Pipeline - Minichart
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):